FUTURE ONCOLOGY

TECHNOLOGY, PRODUCTS, MARKETS AND SERVICE OPPORTUNITIES

A NEW MEDICINE PUBLICATION | VOLUME 2, NUMBER 1-12 INDEX | MAY 1997

TABLE OF CONTENTS

BREAST CANCER — PART II ASYMPTOMATIC POPULATION SCREENING AND SUSCEPTIBILITY TESTING

BREAST CANCER — PART III DIAGNOSIS, STAGING, MONITORING AND PROGNOSIS

MORE ON PROSTATE CANCER

BREAST CANCER — PART IV CURRENT TREATMENT MODALITIES

BREAST CANCER — PART V NOVEL DRUGS IN DEVELOPMENT

OVARIAN CANCER — PART I EPIDEMIOLOGY, MOLECULAR GENETICS, ETIOLOGY AND PATHOGENESIS

OVARIAN CANCER — PART II SCREENING, DIAGNOSIS, STAGING, AND PROGNOSIS

MEETING COVERAGE

ADVANCES IN THE TREATMENT OF PROSTATE CANCER

FROM THE 32ND ANNUAL MEETING OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY PHILADELPHIA, PA, MAY 18-21, 1996

NEW DEVELOPMENTS IN THE TREATMENT OF ADVANCED COLORECTAL CANCER

FROM THE 32ND ANNUAL MEETING OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY PHILADELPHIA, PA, MAY 18-21, 1996

RECENT DEVELOPMENTS IN NUCLEAR MEDICINE

FROM THE 43RD ANNUAL MEETING OF THE SOCIETY OF NUCLEAR MEDICINE DENVER, CO, JUNE 3-6, 1996

NEW DEVELOPMENTS IN THE TREATMENT OF AIDS-ASSOCIATED KAPOSI'S SARCOMA

FROM THE XI INTERNATIONAL AIDS CONFERENCE, VANCOUVER, BC, CANADA JULY 7-12, 1996

CAP CURE'S THIRD ANNUAL SCIENTIFIC RETREAT

INCLINE VILLAGE AT LAKE TAHOE, CA SEPTEMBER 5-8, 1996

OPPORTUNISTIC INFECTIONS IN CANCER PATIENTS

FROM THE 36TH INTERSCIENCE CONFERENCE ON ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (ICAAC), NEW ORLEANS, LA, SEPTEMBER 15-18, 1996

MANAGEMENT OF BREAST CANCER

FROM THE 19TH ANNUAL SAN ANTONIO BREAST CANCER SYMPOSIUM, SAN ANTONIO, TX, DECEMBER 12-14, 1996

A REPORT FROM THE FIFTH INTERNATIONAL CONFERENCE ON GENE THERAPY OF CANCER

NOVEMBER 14-16, 1996, SAN DIEGO, CA

TOPOISOMERASE I INHIBITORS

FROM THE 21ST CONGRESS OF THE EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY (ESMO), VIENNA, AUSTRIA, NOVEMBER 1-5, 1996

TECHNOLOGY UPDATE

CANCER VACCINES — HUMORAL VERSUS CELLULAR IMMUNITY

ISSUES IN ONCOLOGY

RANDOMIZED CLINICAL TRIALS IN ONCOLOGY

ANTI-CANCER DRUG DEVELOPMENT

TOPOISOMERASE I INHIBITORS

CORRECTIONS, ADDITIONS AND AMPLIFICATIONS

LIST OF EXHIBITS

INDEX OF COMPANIES & INSTITUTIONS

FUTURE ONCOLOGY STAFF:

PUBLISHER AND EDITOR:	**Katie Siafaca, MS**
ASSOCIATE EDITOR:	**Sarah Nghiem**
EPIDEMIOLOGY:	**Kristina Lorenson, MPH**
SCIENCE & TECHNOLOGY:	**Diane Etchison, PhD**
CIRCULATION:	**Milan Sheth**
DATABASE MANAGER:	**Richard Glenn Williams**
RESEARCH	**Feisal Yamani and Shaun Gray**
DESIGN & PRODUCTION:	**Jill Burch**

EDITORIAL BOARD

BIOTECHNOLOGY & APPLIED SCIENCES:
James W. Hawkins, PhD, Editor, Antisense Research and Development

CLINICAL PRACTICE:
Ante Lundberg, MD, Dana-Farber Cancer Institute and Harvard Medical School

REIMBURSEMENT AND MANAGED CARE:
Elan Rubinstein, PharmD, MPH, Consultant

TECHNOLOGY AND DEVICES:
Marvin Burns, MBA, President, Bio-Tech Systems

FUTURE ONCOLOGY

TECHNOLOGY, PRODUCTS, MARKETS AND SERVICE OPPORTUNITIES

To date, FUTURE ONCOLOGY has presented:

- A database of over 700 agents in development for the treatment of cancer
- Detailed incidence and mortality estimates as well as selected epidemiologic data by cancer type and stage and type of treatment, etc., for the USA, Europe, Japan and other world regions
- Current and forecast drug markets, worldwide
- Profiles of over 80 commercial programs in the oncology area
- Detailed descriptions of putative mechanisms of carcinogenesis
- In-depth discussions of product development strategies
- Attendance and coverage of over 30 meetings in the cancer and related fields



FUTURE ONCOLOGY SEPTEMBER 1995 VOLUME 1, NUMBER 5

Exhibit 7
Combination Approaches in Clinical Trials Against MDR Cancers

MDR-reversing Agent	Chemotherapeutic Agent	Status/Location/Indication
SDZ PSC 833 (5 mg/kg, PO qid)	Paclitaxel (60-80 mg/m², IV)	Phase I/USA/solid tumors (ASCO95, Abs.
SDZ PSC 833 (12.5 mg/kg PO,q 12 hours for 8 days)	Vinbla IV q d	
SDZ PSC 833 (4 mg/kg q 8 hours 8 times)	Doxor (0.5 m (750 m	
SDZ PSC 833 (5 mg/kg q 6 hours or 20 mg/kg/d)	Etopo	
S 9788 (escalating continuous IV infusion of 160, 240, 320, 400, 480 mg over 6 hours)	Doxor after S	
S 9788 (MTD was 96-104 mg/m² as a 30 minute IV infusion)	Doxor	
VX-710	Paclita	
VX-710	Doxor	
L-S, R-buthionine sulfoximine (BSO) (0.75 g/m²/h x 24 to 1.5 g/m²/h x 48, (Continuous infusion)	Melph	
Dexniguldipine (oral)	Daun	
Mitotane (escalating; starting at 4 gm, 5 gm and 6 gm, PO, q week 3 hours prior to vinblastine)	Vinbla	
IFN-α 2b (escalating dose from 0.5 mu/m² to 1 mu/m² on days 5-9) + hydroxyurea (500 mg q 8 hours, days 5-9) + tamoxifen (40 mg/m², days 1-10) + streptozocin (500 mg/m², days 6-9)	BCNU	
Intracellular histamine antagonist N, N-diethyl-2-[4-(phenylmethylphenoxy] ethanamine-HCl (DPPE) (240 mg/m² over 80 or 440 minutes weekly)	Variou the pa	
L-verapamil (125 mg/m² PO q 4 hours beginning 24 hours before and continuing for 24-hours after paclitaxel infusion)	Paclita 96-ho	
Dexverapamil (240-1200 mg/m²/day)	Etopo (1.6 m contin cyclop predn	
Dexverapamil (3000 mg/d)	Vinbla	
Dexverapamil (begun 18 hours before day 1 of vinblastine administration and given orally every 6 hours (either as a 120 mg/m2 dose or a 180 mg/m2 dose plus dexamethasone) for 12 doses)	Vinbla on day	
Etanidazole (16 g/m² by 96-hour continuous infusion)	Ifosfa (1.6-1 autolo	

COPYRIGHT

FUTURE ONCOLOGY AUGUST 1995 VOLUME 1, NUMBER 4

Exhibit 2
Lung Cancer Incidence and Mortality by Gender in Selected Countries Worldwide in 1995

Country	Death Rate Male	Female	Total	Total Deaths	Incidence Rate Male	Female	Total	Total Incidence
Group 1								
UK	99.7	44.1	71.3	41,447	105.7	52.9	78.8	45,763
Germany	78.0	18.2	47.3	38,426	82.7	21.8	51.4	41,795
Italy	101.7	16.6	58.0	33,574	107.8	19.9	62.6	36,280
France	90.1	12.2	50.2	28,992	95.5	14.6	54.1	31,237
Spain	76.0	7.3	41.1	16,145	80.6	8.8	44.1	17,317
Holland	100.9	17.4	58.7	9,105	107.0	20.9	63.5	9,842
Belgium	128.2	15.6	70.8	7,099	135.9	18.7	76.1	7,637
Greece	88.1	14.7	50.8	5,212	93.4	17.6	54.9	5,632
Denmark	82.8	46.5	64.4	3,345	87.8	55.8	71.6	3,717
Portugal	47.2	9.9	27.9	2,759	50.0	11.9	30.3	2,995
Ireland	63.4	28.6	46.0	1,595	67.2	34.3	50.7	1,760
Subtotal	89.1	20.1	53.8	187,699	94.4	24.1	58.4	203,975
Group 2								
Austria	72.1	21.5	45.9	3,608	76.4	25.8	50.2	3,947
Sweden	45.9	21.3	33.5	2,937	48.7	25.6	37.0	3,246
Switzerland	71.6	13.8	42.2	2,933	75.9	16.6	45.7	3,178
Finland	64.5	14.9	39.0	1,970	68.4	17.9	42.4	2,142
Norway	53.2	20.2	36.5	1,591	56.4	24.2	40.2	1,749
Subtotal	60.1	18.3	38.8	13,039	63.7	22.0	42.4	14,261
Group 3								
Poland	90.3	16.8	52.6	20,387	95.7	20.2	57.0	22,078
Yugoslavia (old)	67.7	12.3	39.7	9,576	71.8	14.8	43.0	10,361
Czech Republic	100.1	15.8	56.9	9,032	106.1	19.0	61.4	9,753
Hungary	125.8	30.6	76.3	7,994	133.3	36.7	83.1	8,707
Romania	55.4	10.7	32.8	7,705	58.7	12.8	35.5	8,346
Bulgaria	64.6	12.5	38.1	3,382	68.5	15.0	41.2	3,665
Subtotal	81.4	15.5	47.8	58,077	86.2	18.6	51.7	62,908
Group 4								
Old USSR	65.4	7.2	34.7	99,147	69.3	8.6	37.3	106,619
Group 5								
USA	74.1	46.0	59.8	157,400	74.6	54.8	64.6	169,900
Group 6								
Japan	49.0	17.2	32.8	40,563	51.9	20.6	36.0	44,511
Canada	77.2	31.9	54.2	13,730	81.8	38.3	59.8	15,127
Argentina	46.9	8.3	27.2	8,871	49.7	10.0	29.4	9,596
Australia	60.3	19.5	39.8	6,212	63.9	23.4	43.6	6,798
Cuba	49.8	18.3	34.2	3,328	52.8	22.0	37.5	3,651
Hong Kong	62.1	31.6	47.1	2,603	65.8	37.9	52.1	2,879
Chile	17.6	6.5	12.0	1,582	18.7	7.8	13.1	1,738
New Zealand	57.6	25.1	41.2	1,362	61.1	30.1	45.4	1,503
Uruguay	83.8	7.3	44.6	1,317	88.8	8.8	47.8	1,411
Singapore	42.2	16.3	29.4	796	44.7	19.6	32.3	874
Israel	27.8	10.7	19.2	776	29.5	12.8	21.1	853
Costa Rica	11.1	5.5	8.3	201	11.8	6.6	9.2	222

85

COPYRIGHT © 1995 NEW MEDICINE, INC. 714. 830. 0448.

New ONCOLOGY KNOWLEDGEbase & ONCOLOGY DRUGS DATAbase



ONCOLOGY DRUG DATAbase

PRODUCT DESIGNATION

Generic Name	MAb B43.13
Brand Name	Ovarex
Description	Anti-idiotypic MAb that binds CA 125-expressing tumor cells and elicits an immune response via generation of autologous antigen mimics.

PRODUCT SOURCE

Primary Developer	AltaRex
Affiliate(s)	Biomira; Medac GmbH; MerckFrosst Canada
Description	Pursuant to an agreement entered in November 1995, Biomira out-licensed its antibody MAb B43.13 to AltaRex to be incorporated into the Ovarex vaccine. AltaRex paid an upfront licensing fee and will make royalty payments on any profits from net sales. In August 1996, AltaRex and Medac entered a strategic partnership. In return of Western European marketing rights for Ovarex for ovarian cancer, Medac is obligated to fund European clinical trials and product registration fees. Medac has also agreed to purchase Ovarex from AltaRex at specifically agreed upon transfer prices. MerckFrosst Canada manufactures Ovarex for AltaRex.

PRODUCT SPECIFICATIONS

Therapeutic Indication	Malignancy
Therapeutic Category	
Drug Category	
Drug Class/Type	
Technology	
Mechanism	
Target	
Administration Route	
Cancer Indication	

CLINICAL STATUS BY IND

Indication	
Latest Status	
Clinical History	

MARKET STATUS

Drug Status	
Comments	

BRIANA BIO-TECH

BRIANA BIO-TECH (Edmonton, Ontario, Canada) is a biopharmaceutical company focused on the commercial development of therapeutics and diagnostics for treating cancer and neurological disorders. In return of exclusive worldwide distribution rights to the technology stemming from research conducted by Dr. Lung-Ji Chang's team at the University of Alberta, Briana Bio-Tech entered a three-year funding agreement to support clinical trials and ongoing research and development for the technology. The University of Alberta received an initial payment of (Cdn) $200,000 and anticipates (Cdn) $300,000 to fund the first year of research. Briana Bio-Tech plans to complete a private placement by July 1997 to raise an additional (Cdn) $8 million.

Dr. Chang is developing an immunogene cancer therapy to induce an enhanced immune response that will be entering phase I clinical trials in June 1997 in 5 advanced brain cancer and 5 melanoma patients at the University Hospitals in Edmonton. Immunogene therapy combines two genes, one of which is B7-2 that has never been tested in cancer clinical trials. The vaccine may have potential application in other tumors such as breast cancer. Briana Bio-Tech is actively pursuing other strategic alliances and collaborations in oncology and neurology.

AFFILIATIONS

University of Alberta	Briana Bio-Tech has licensed the research and is funding the clinical trials and the ongoing research and development for this promising technology for at least the next three years. Briana Bio-Tech obtained an exclusive worldwide distribution rights to immunogene therapy.

IMMUNOTHERAPEUTIC/VACCINE PIPELINE

GenericName ❑ Number ❑ Brand Name	Affiliations	Class ❑ Type ❑ Target ❑ Mechanism	Clinical Status
Immunogene therapy	University of Alberta	Immunomodulator	Phase I (b6/97)➢Canada ❑ advanced brain cancer, malignant melanoma

NEW MEDICINE
P.O. Box 909
Lake Forest, CA 92630

BULK RATE
U. S. POSTAGE
PAID
EL TORO, CA
PERMIT #277